Global contract development and manufacturing organization (CDMO), Recipharm, has unveiled an investment and capacity expansion at its facility in Israel. This investment will support customers’ growing demand for cGMP clinical supply of active pharma ingredients (API) and intermediates and is part of an integrated plan to enhance Recipharm’s offering in drug substances services.
 
The investment will see the implementation of a full GMP chemical unit including a number of brand-new R&D laboratories and technologies. This will allow Recipharm to support customers through their development projects, from early medicinal chemistry into commercialization, through a single integrated flow. The expansion is expected to be fully operative by the end of 2021.
 
“Recipharm is proud to making this investment. It will be unique in Israel, where we have a talented team who excel at bringing customers molecules to life,” said Bernard Pluta, president development services, Recipharm. “Complementing our API development and manufacturing facilities in Europe, the investment provides our customers with a reliable value chain of quality APIs; which will ultimately benefit patients.”
 
Recipharm’s facility in Israel is located south of Tel Aviv in the vicinity of the Weizmann Science Park. The team specializes in medicinal chemistry. The offering includes a wide array of services in chemical synthesis and analysis including some very demanding and novel specialties. The company also offers analytical and pre-clinical services.